Company: BLRX
Filing Date: 2025-07-25
Form Type: 424B5
Source: 0001178913-25-002463
Chunk: 0

Company: BioLineRx Ltd.
Filing Date: 2025-07-25
Form: 424B5
Chunk 0
---
#### Filed pursuant to Rule 424(b)(5)

#### Registration No. 333-276323

#### PROSPECTUS SUPPLEMENT
**(To prospectus dated January 5, 2024)**

#### BioLineRx Ltd.
<div align='center'>**Up to $4,870,000 of 
 American Depositary Shares Representing Ordinary Shares**</div>

**We are filing this prospectus supplement to amend the prospectus, dated January 5, 2024, filed as a part of our registration statement on Form F-3 (File No. 333-276323), or the
      Registration Statement, as supplemented by our prospectus supplement, dated April 11, 2025, or the Prior Prospectus, to update the maximum amount of securities we are eligible to sell under our Registration Statement pursuant to General Instruction
      I.B.5 of Form F-3. This prospectus supplement amends and supplements the information in the Prior Prospectus relating to the offering, issuance and sale by us of our American Depositary Shares, or ADSs, representing our ordinary shares, par value NIS
      0.10 per share, from time to time that may be issued and sold under the at-the-market offering agreement, dated September 3, 2021, or the Offering Agreement, by and between us and H.C. Wainwright & Co., LLC, or Wainwright, as sales agent. This
      prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This
      prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

As a result of these limitations and the current public float of our ordinary shares, including ordinary shares represented by ADSs, and in accordance with the terms of the Sales
      Agreement, we may offer and sell ADSs having an aggregate offering price of up to $4,870,000 from time to time through Wainwright, which does not include the ADSs having an aggregate sales price of approximately $3.2 million that were sold pursuant
      to the Prior Prospectus to date.

Our ADSs are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “BLRX”. On July 24, 2025,